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Infections caused by lentiviruses, including human immunodeficiency virus, are characterized by slowly
progressive disease in the presence of a virus-specific immune response. The earliest events in the vims-host
interaction are likely to be important in determining disease establishment and progression, and the kinetics ofthese
early events following lentiviral infection are described here. Lymphatic cannulation in the sheep has been used to
monitor both the virus and the immune response in efferent lymph after infection ofthe node with maedi-visna virus
(MVV). Viral replication and dissemination could be detected and consisted ofa wave ofMW-infected cells leaving
the node around 9 to 18 days postinfection. No cell-free virus was recovered despite the fact that solubleMW p25
was detected in lymph plasma. The maximum fiequency ofMW-infected cells was ony 11 in 10' but over the first
20 days of infection amounted to greater than 104 virus-infected cells leaving the node. There was a profound
increase in the output of activated lymphoblast from the lymph nodes of infected sheep, characterzed by an
increased percentage of CD8+ lymphoblasts. All of the CD8+ lymphoblasts at the peak of the response expressed
both major histocompatibility complex class H DR and DQ molecules but not interlieukin-2 receptor (CD2S). The
in vitro proliferative response ofefferent lymph cells exiting the node after challenge with MVV to both recombinant
human interleukin-2 and the mitogen concanavalin A was decreased between days 8 and 16 postinfection, and a
specific proliferative response to MVV was not detected until after day 15. Despite the high level of CD8+
lymphoblasts in efferent lymph, direct MVW-specific cytotoxic activity was demonstrated in only one of the five
MVW-challenged sheep. MW-specific antibody responses, including neubalization and MW p25 immune
complexes in efferent lymph, were detectable during the major period of virus dissemination. The relationship of
these findings to the evasion of the host's acute immune response by MVW is discussed.
Lentiviral infections of humans and animals result in
disease characterized by a long incubation period and a slow
progression of disease (45). The course of lentiviral infection
can be divided into a number of stages: (i) primary exposure
to virus leading to the establishment of infection; (ii) a
prolonged, largely asymptomatic incubation period of the
virus in the host, with gradual development of pathological
lesions in a variety of organs and tissues; and (iii) a decline
into patent disease and death (40).
Persistent infection with a lentivirus is characterized by
continuous viral replication, but this occurs in the face of a
vigorous host immune response (24, 45). Studies on the
nature of the interactions between the virus and the host
immune response are therefore of special interest in under-
standing the pathogenesis of lentiviral disease. The patho-
physiological events occurring immediately postinfection
(p.i.) and in the interval between infection and diagnosis
remain obscure, yet these early stages of the infective
process are likely to have a significant influence on the
establishment of infection and hence the progress of disease.
In human immunodeficiency virus (HIV), there is evidence
that early immune selection of infecting virus subtypes can
dramatically alter the time course of disease (64). It is also at
this time that any immune mechanisms induced by prior
vaccination must act to prevent or clear viral infection.
Lymphoid tissue is the major site of any specific immune
reaction and continuing lentiviral replication during disease
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progression (10, 50). A unique in vivo model for investigating
different phases of the lentivirus-host immune response
interaction is provided in the sheep by combining cannula-
tion of the efferent lymphatic vessels (26) with infection of
sheep with the ruminant lentivirus maedi-visna virus (MVV).
This technique has allowed direct access to the lymphatic
output of a node for analysis (65) after acute local infection
with MVV in this study.
MVV was the first discovered lentivirus (23, 62), although
HIV-1 is now the best-characterized member of this group of
viruses. MVV is known to infect cells of the monocyte/
macrophage lineage and possibly dendritic cells but not lym-
phocytes (16, 17, 19, 46). This restriction in tropism makes the
study of MVV infection a valuable model for understanding
lentiviral pathogenesis in the absence of T-cell infection.
Clinical MVV infection consists of a multisystem disease
characterized by chronic active inflammation, presenting as
interstitial pneumonitis (maedi), demyelinating leukoenceph-
alomyelitis (wasting or visna), and mastitis (7, 23).
In this report, the major features of the acute immune
response to MVV infection and viral dissemination are
described and the relevance of these data to the failure of the
immune system to prevent the establishment of a persistent
infection is discussed.
MATERIALS AND METHODS
Animals. Finnish Landrace sheep (1 to 3 years of age)
were purchased from the Moredun Research Institute, Ed-
inburgh, Scotland.
Prefemoral or popliteal efferent lymphatic cannulations
were performed as described previously (25, 26). Not less
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than 5 days postcannulation, sheep were injected subcuta-
neously with 2 to 5 ml of mock-infected or virus-infected
autologous cell supernatant (105 to 106 50% tissue culture
infective doses [TCID50J; see Table 3) at several sites within
the drainage area of the cannulated lymph node.
Skin cell lines and virus culture. Autologous skin cell lines
for each sheep were derived from skin biopsies taken at least
2 months prior to cannulation. The biopsies and cell lines
were prepared by the method of Liu and Karasek (33) as
modified by Rheinwald and Green (55).
Ninety percent confluent skin cell monolayers were in-
fected with 0.1 TCID50 ofMW strain EV1 61 (EV1) per cell
in Dulbecco modified Eagle medium (DMEM) supplemented
with 2 mM L-glutamine, 100 U of benzyl-penicillin per ml,
100 U of streptomycin per ml, and 2% fetal calf serum (FCS)
(2% DME). When extensive cytopathic effects were seen
(usually 5 days p.i.), the virus-containing cell supernatant
was harvested, clarified by centrifugation (800 x g, 20 min),
and stored at -70°C. The titer of each virus stock was
determined on autologous skin cell monolayers, and the
concentration was calculated by using the quantal method of
Reed and Muench (43). Mock-infected antigen was prepared
as described above from day 5 mock-infected skin cell
cultures.
Analysis of efferent lymph. Lymph was collected into
sterile plastic bottles containing 909 U of benzyl-penicillin
and streptomycin and 250 U of sodium heparin (Sigma
Chemical Co. Ltd.). Bottles were changed three times daily;
short (2-h) day collections were used for fluorescence-
activated cell sorting (FACS) analyses, and overnight col-
lections were used for functional analyses. Cells were rou-
tinely >99% viable as detected by trypan blue dye exclusion.
The volume and cell concentration of each collection were
recorded. Cells were resuspended in 10% dimethyl sulfox-
ide-90% FCS for freezing slowly at -80°C or under liquid
nitrogen.
Immunofluorescence analysis of cell phenotype. Ovine
CD4+ and CD8+ lymphocytes were identified by using
monoclonal antibodies (MAbs) SBU-T4 and SBU-T8, re-
spectively (37). The sheep homologs of major histocompat-
ibility complex (MHC) class II DQ and DR were detected by
using the locus-specific anti-a-chain MAbs VPM 36 (DQ)
and VPM 38 (DR) (8, 9). Interleukin-2 (IL-2) receptor
(IL-2R; CD25) was detected by using IL-Alll (44). VPM 8
(2) recognizes sheep immunoglobulin light chain (IgL). ZG4
(34), an anti-human IgG3, or diluted normal mouse serum
was used as a negative control. For two-color analysis, the
CD4- and CD8-specific MAbs (both IgG2a) were biotinylated
and detected with streptavidin-phycoerythrin (Sero-Tec;
Oxford, England). The anti-MHC class II and IL-2R MAbs
(all IgGl) were detected by using anti-mouse IgGl-fluores-
cein isothiocyanate (FITC) (The Binding Site, Birmingham,
England). Analysis was carried out on a Becton Dickinson
FACScan (Becton Dickinson, Mountain View, Calif.). Ten
thousand total efferent lymph cells with erythrocytes or dead
cells excluded on the basis of forward scatter (FSC) and
4,000 efferent lymphoblasts (defined by a gate based on their
larger size [FSC] and higher side scatter [SSC] properties
than those for small lymphocytes [Fig. 1A]) were analyzed
per sample, using Consort 30 Version F (Becton Dickinson).
Analysis gates were set for strongly positive CD4- and
CD8-staining cell populations, and the MHC class II and
IL-2R expression on these CD4+ and CD8+ cell populations
was assessed.
Quantitation of MIWgag p25. The method is described in
reference 54. Briefly, enzyme-linked immunosorbent assay
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FIG. 1. Major phenotypic change of efferent lymph cells after
infection with MVW. (A) FSC and SSC FACS profiles of efferent
lymph cells. Sheep 657R was challenged with MVV in the region
draining to the prefemoral lymph node, which had been cannulated.
The FSC and SSC profiles (both linear scale) of the efferent lymph
cells on day 11 p.i. are shown along with representative samples of
the lymphoblast collection box (high FSC) and small lymphocyte
analysis box (low FSC). (B) Kinetics of CD8+ lymphoblast output of
a lymph node after MVV infection. Sheep were challenged in the
region draining to the cannulated lymph node on day 0 with MVV
(open symbols) or mock-infected control antigen (closed symbols).
CD8+ lymphoblasts were determined by immunostaining and FACS
analysis. Sheep: 0, 657R; 0, 649R; *, 1060P; 0, 663R. (C) MHC
class II expression on efferent lymph CD8+ lymphoblasts. Efferent
lymph cells were double stained with SBU-T8 (anti-CD8) and
normal mouse serum ( ), VPM 38 (anti-DR) (.), or VPM 36
(anti-DQ) ( ). MHC class II expression on CD8+ lymphoblasts is
shown for sheep 649R on day 5 p.i., the peak of this sheep's CD8+
lymphoblast response.
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(ELISA) plates were coated with affinity-purified rabbit
antibody to recombinant MW p25. Lymph plasma was
titrated down the plates, with purified recombinant p25 used
as a standard. The plates were then developed with biotiny-
lated rabbit anti-MVV p25, Extravidin-horseradish peroxi-
dase (Sigma), and o-phenylenediamine. This assay could
detect a minimum of 150 to 300 pg ofMVV p25 per ml.
Quantitation of infectious MVV. Infectious virus was de-
tected by cocultivation of serial dilutions of lymph plasma or
cells on heterologous sheep skin fibroblast monolayers in 2%
DME. For cell-associated virus, 107 cells stored at -80°C
were thawed rapidly at 37°C, washed once in 2% DME,
resuspended in 2% DME, counted, and titrated in triplicate
in a sixfold-dilution series onto the fibroblast monolayer.
Lymph plasma was similarly assayed for infectious MVV
from a 1/2 dilution. The monolayers were cultured for 12 to
14 days and then washed in Hanks balanced salt solution,
fixed, and stained for MVV gag p15 (MAb 415 kindly
donated by D. J. Houwers) or gag p25 antigen (MAb ID10
[54]) by immunofluorescence. The monolayers were blocked
in phosphate-buffered saline (PBS)-10% sheep serum-0.01%
Tween 80, incubated with MAb ascites fluid diluted in
PBS-2% sheep serum-0.1% Tween 80 (PST), then in sheep
anti-mouse Ig-biotin conjugate (Sigma) in PST, and finally in
Extravidin-FITC (Serotec) in PST, with washes after each
step, and assessed for FITC-positive fluorescence micro-
scopically. Positive controls were 72-h MVV EV1-infected
fibroblasts. Negative controls included an irrelevant mouse
IgG2a MAb and uninfected fibroblasts stained with MVV-
specific MAb.
Detection of viral DNA. Cells (107) stored at -80°C were
thawed, washed twice in PBS, and resuspended in 400 ,ul of
cell lysis buffer (0.5% sodium dodecyl sulfate [SDS], 50 mM
Tris-HCl [pH 8.0], 0.1 M NaCl, 1 mM EDTA). DNA was
prepared by standard methods (42), including RNase A and
proteinase K digestions. For MVV DNA detection by the
polymerase chain reaction (PCR), 500 ng of lymph cell DNA
(equivalent to 1.7 x 105 cells) was used as a substrate in an
amplification primed with MVV EV1 long terminal repeat
(LTR)-specific amplifiers 591H (CTGCAGGTCGACTGT
CAGGGCAGAGAACAG, equivalent to positions 8913 to
8933 on the EV1 genome, sense strand [61], plus 5' additions
not relevant to this work) and 592H (TCTAGAGTCGA
CAGCTGCGAGACCCGCTCCG, equivalent to positions
152 to 133, antisense strand, plus 5' additions not relevant to
this work). PCR was carried out in a volume of 100 pl, using
1.6 U of Taq polymerase in the buffer conditions of Ohara et
al. (49) and 4 cycles of 95°C for 0.6 min, 62°C for 0.6 min, and
72°C for 1 min, followed by 26 cycles of 95°C for 0.6 min,
72°C for 1.5 min, and 72°C for 2 min and a single termination
cycle of 72°C for 7.5 min. For the ethidium bromide-stained
gel, the reaction mixture was diluted 10-fold, and 2 p1l was
then amplified through a further 15 cycles with internal 310L
(ATGCCCATGATTGAGAATGAC) and 555H (ACAGC
CAACTCCTTTATTA) primers as in cycles S to 30 above.
As a positive control, 500 ng of extrachromosomal DNA
from MW EV1-infected fibroblasts was prepared by the
method of Hirt (27) and amplified in the same way. Ten
microliters of the PCR products was analyzed by electro-
phoresis on 1.5% agarose TAE gels, blotted onto nitrocellu-
lose, and hybridized with an EV1 LTR-specific cloned
probe, using standard methods (42).
V'irus neutralizing antibody. Serial dilutions of heat-inacti-
vated lymph plasma (56°C, 30 min) were incubated overnight
at 4°C with 500 TCID50 of MVV EV1. The plasma-virus mix
was then titrated along a flat-bottom 96-well plate (GIBCO-
BRL, Paisley, Scotland) containing a preformed fibroblast
monolayer and incubated for 2 h at 37°C. The virus inoculum
was then replaced with 2% DME, and after 7 days of
incubation, the cells were fixed, Giemsa stained, and exam-
ined microscopically for MVV cytopathic effects. Neutral-
ization titers were defined as the greatest dilution of lymph
plasma giving a 50% reduction in virus titer compared with
controls (virus incubated with preimmune plasma or no
plasma).
Detection of anti-MW gag p25. Purified recombinant p25
(54) was coated onto ELISA plates (Falcon 3912) at 10,ug/ml
overnight at 4°C. Plates were washed, blocked with borate-
buffered saline-1 mg of bovine serum albumin (BSA) per ml,
and then lymph plasma was titrated down the plate in
borate-buffered saline-BSA-0.05% Tween 20. After 1 h of
incubation, the plates were washed and developed with
horseradish peroxidase-conjugated rabbit anti-sheep Ig
(Dako Ltd., High Wycombe, England) and o-phenylenedia-
mine. Antibody titer was expressed as the end point titer,
taken as the reciprocal of the highest dilution of plasma
which gave an optical density twice that of the control (no
plasma).
Detection of MVV gag p25-sheep Ig immune complexes.
MVV p25 in lymph plasma was captured by rabbit anti-MW
p25 as described above, but then the plates were incubated
with rabbit anti-sheep Ig conjugated to horse-radish peroxi-
dase and developed as described above. Increasing values of
optical density at 492 nm were taken as evidence of immune
complex formation.
Proliferation of efferent lymph cells to recombinant human
IL-2 and ConA. Efferent lymph cells were washed and then
resuspended at 106 cells per ml in RPMI 1640 (catalog no.
074-1800; GIBCO-BRL) fully supplemented with 2 mM
L-glutamine, 5 x 10-5 M 2-mercaptoethanol, 200 ,ug of
gentamicin per ml, and 10% FCS (RPMI-10% FCS).
Then 105 cells per well in 96-well flat-bottom plates were
cultured in triplicate with an equal volume of RPMI-10%
FCS with final concentrations of recombinant human IL-2
(National Institute of Biological Standards and Control,
Potters Bar, England) or concanavalin A (ConA; catalog no.
C7275; Sigma) of 20 U/ml or 5 jig/ml, respectively, for 3 days
at 37°C in 5% CO2. Cultures were labeled with 1 ,uCi of
[3H]thymidine (20 to 30 Ci/mmol; catalog no. TRK61; Am-
ersham International PLC) per well and incubated for 5 h at
37°C in 5% CO2. Cultures were harvested onto Skatron glass
fiber filter mats (Skatron Instruments Ltd.) and counted in a
LKB Wallac 1218 Rackbeta liquid scintillation counter.
Results have been expressed as specific proliferation =
(mean cpm of stimulated cultures) - (mean cpm of unstim-
ulated cultures).
Proliferation of efferent lymph cells to MVV antigen. Effer-
ent lymph cells (105) in RPMI-10% FCS were plated with 3
x 105 autologous peripheral blood mononuclear cells
(PBMC) as antigen-presenting cells and 4 ,ug of sucrose-
purified MW antigen per ml in triplicate in 96-well flat-
bottom plates for 5 days at 37°C in 5% CO2. Cultures were
labeled and harvested as for recombinant human IL-2- and
ConA-stimulated cultures, and the results have been ex-
pressed as stimulation index = (mean cpm of antigen-
stimulated cultures/mean cpm of unstimulated cultures).
Autologous PBMC were collected prior to MVV challenge
and cryopreserved. They proliferated in response to ConA
but did not proliferate in response to either sucrose-purified
MVV antigen or recombinant gag p25 MVV antigen (data
not shown). MVV antigen was prepared from supernatants
of infected cell cultures showing extensive cytopathic ef-
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TABLE 1. Summary of the lymphoblast response in efferent lymph to challenge of the lymph node by MVV
% Lymphoblasts % CD4+ lymphoblasts % CD8+ lymphoblasts Lymphoblast CD4/ % Ig+ lymphoblastsCD8 ratio Iglmhbas
Sheep no.Sheepno.
~ Maximum Maxiurn Maximum Minimum MaximumDay 0" (day p.i.)b DayO (day p.i.) Day 0 (day p.i.) Day 0 (day p.j.)C Day 0 (day p.i.)
EV1 infected
657R 3.9 19.2 (12) 65.1 66.7 (6-7) 20.5 53.3 (9) 3.2 0.5 (9) 21.2 46.9 (21)
649R 8.9 36.3 (7) 36.4 51.2 (2) 16.8 48.8 (5) 2.2 0.4 (7) 27.0 31.0 (9)
683R 4.0 20.3 (16) 39.5 51.2 (9) 20.6 31.2 (11) 1.9 1.1 (11) 29.1 45.9 (20)
671R 2.8 30.0 (7) 37.2 40.1 (4) 8.9 80.0 (7) 4.2 0.2 (7) 50.1 43.1 (11)
672R 2.8 47.6 (8) 51.5 65.7 (2) 22.6 84.9 (6) 2.3 0.2 (6) 14.1 59.0 (9)
Mock infected
1060P 4.7 11.7 (5) 64.5 65.0 (16) 18.0 26.0 (16) 3.6 2.5 (19) 10.7 26.8 (19)
663R 4.5 4.6 (8) 45.0 58.0 (15) 11.6 23.7 (5) 7.5 1.7 (5) 31.0 32.1 (11)
647R 3.8 11.0 (2) 50.0 58.2 (6) 6.0 10.0 (3) 8.3 5.3 (3) 16.9 23.5 (5)
EV1 infected, median 3.9 30 39.5 51.2 20.5 53.3 2.3 0.4 27.0 45.9
Mock infected, median 4.5 11.0 50.0 58.2 11.6 23.7 7.5 2.5 16.9 26.8
Pd 0.551 0.037e 0.551 0.766 0.233 0.037e 0.074 0.037e 0.551 0.074
a Values shown preinfection on the day sheep were challenged.
b Maximum values seen p.i., with the day p.i. when this occurred in parentheses.
c Minimum values seen p.i., with the day p.i. when this occurred in parentheses.
d Differences between the groups were analyzed by using Mann-Whitney two-tailed tests.
Differences between groups considered significant ifP is <0.05.
fects, which were clarified by centrifugation at 10,000 x g at
4°C for 30 min, and virus was then pelleted at 10,000 x g at
4°C for 16 to 18 h and resuspended in PBS. Pelleted virus
was purified on 25 to 60% sucrose gradients at 100,000 x g at
4°C for 16 h, gradient fractions containing reverse tran-
scriptase activity and viral proteins (determined by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis analysis)
were pooled, and the virus was pelleted at 100,000 x g at 4°C
for 16 h. Purified virus was stored at -80°C, and optimum
concentrations for use were determined by titration in pro-
liferation assays with PBMC from persistently MVV-in-
fected sheep.
Cytotoxic activity of efferent lymph cells. Efferent lymph
cells were centrifuged over Lymphoprep (Nycomed AS) at
800 x g for 15 min, and interface cells were washed twice
with RPMI-2% FCS before resuspension in RPMI-10% FCS
with 10mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfon-
ic acid (HEPES; pH 7.2). Cells were made to the required
concentration for effector/target ratios of 100:1 to 12:1 before
incubation with target cells for 6 h at 37°C in 5% CO2.
Targets were 104 autologous or heterologous skin cells either
mock infected or infected with 0.25 to 2 TCID50 (depending
on virus stock) per cell for 72 h. Cells were labeled with 3
,uCi of 51Cr (sodium chromate; 350 to 600 mCi of Cr per mg;
Amersham) per 104 cells overnight at 37°C in 5% CO2 before
being washed four times with RPMI-2% FCS and were then
incubated with efferent lymph effector cells for 6 h. Super-
natant (100 p,l) was counted in a LKB Wallac 1274 RIA-
GAMMA counter, and the results have been expressed as
percent specific 51Cr release = (mean experimental 51Cr
release - mean spontaneous 51Cr release)/(mean maximum
51Cr release - mean spontaneous 51Cr release) ± (standard
deviation of experimental 51Cr release)/(mean maximum
51Cr release - mean spontaneous 51Cr release). All values
were obtained from quadruplicate samples, and spontaneous
51Cr release was always less than 35% of the maximum
release.
RESULTS
Kinetics and phenotype of cells in efferent lymph after
challenge of a lymph node with MVV. Eight peripheral
efferent lymphatic cannulations were carried out, five in-
volving prefemoral nodes and three involving popliteal
nodes. Challenge was with either mock-infected autologous
cell supernatant or MW (from approximately 1.5 x 105 to
16 x 105 TCID5O). There was no significant difference in the
total cell output between MW-infected and mock-infected
sheep (data not shown) with the exception that cell shut-
down occurred in three of the five infected animals and never
in the mock-infected animals. Cell shutdown of the lymph
node (cells are retained within the node) is a normal response
to secondary antigenic challenge (39), although it has been
shown to occur on primary challenge when other live viruses
are used (31, 63). However, in these experiments, the
phenomenon was not related to the amount of virus given or
the lymph node efferent duct cannulated (data not shown).
Following MVV infection, there was no significant in-
crease in total cell output in the infected group compared
with mock-infected controls. The proportion of lymphoblast
defined by their FSC/SSC profile on the FACScan (Fig. 1A)
was markedly increased in infected sheep (Table 1), with a 4-
to 17-fold increase in the percent lymphoblasts from day 0 to
the day p.i. showing the maximum percent lymphoblasts
(days 7 to 16 p.i.). There was only a 1- to 3-fold increase in
mock-challenged sheep (Table 1).
The lymphoblast population comprises mainly CD4+,
CD8+, and B-lymphoblast cells. There was no significant
difference in the maximum percent CD4+ lymphoblasts in
the two groups of animals (P = 0.766; Table 1). However,
there was a marked rise in the proportion of CD8+ lympho-
blasts exiting the node in response to challenge with virus
but not mock-infected antigen (Fig. 1B). These CD8+ cells
left the node as a wave, with maximum percentages being
seen between days 6 and 11 p.i., depending on the sheep
(Table 1). The maximum percent CD8+ lymphoblasts seen
varied significantly between MW-infected and mock-chal-
J. VIROL.
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lenged groups (P = 0.037; Table 1). As the percent CD8+
lymphoblasts increased, there was a concomitant fall in
percent CD4+ lymphoblasts (data not shown), although later
in the response, these figures were also affected by increas-
ing numbers of B lymphoblasts. This is reflected in the
CD4/CD8 lymphoblast ratio, which may drop as low as 0.2
from a median starting ratio of 2.3 (Table 1). When the
percent CD8+ cells in the small lymphocyte population was
studied, none of the changes seen in the lymphoblast popu-
lation were noted with the percent CD8+ small lymphocytes,
remaining constant throughout the course of the cannulation
(data not shown).
The large size of the CD8+ lymphoblasts suggested that
they were becoming activated. The levels of expression of
different MHC class II loci on T lymphocytes are often an
indication of the activation state of the cell, with DQ being
associated with an activated phenotype (12, 32). To investi-
gate the activation state of lymphocytes exiting peripheral
lymph nodes after challenge with MVV, the expression of
the sheep DR and DQ MHC class II homologs was studied
by double staining with anti-CD4 or anti-CD8. CD8+ lym-
phoblasts from the preinfected node showed heterogeneous
staining intensity (100 to 103 FL1 intensity) for both DR and
DQ MHC class II molecules, and this phenotype was seen
throughout the response in mock-infected sheep (data not
shown). In response to live viral challenge, the wave of
CD8+ lymphoblasts exiting the node appeared to be a
homogeneous population in its expression of a high level of
DR and a low level of DQ MHC class II molecules (Fig. 1C).
This change always occurred in virus-challenged sheep on
the day with the maximum percent CD8+ lymphoblasts and
then decayed with time to a staining pattern similar to that
seen in resting efferent lymphoblasts. Similarly, both MHC
class II molecules were expressed with a broad spectrum of
staining intensity on CD4+ lymphoblasts preinfection. How-
ever, although a change was seen in the MHC class II profile
of CD4+ lymphoblasts after challenge, there were no signif-
icant differences between MVV- and mock-infected animals
(data not shown).
The change in MHC class II profile of the CD8+ lympho-
blasts in response to MVV suggested that these cells were in
an activated state. It was therefore expected that the lym-
phoblasts would also express IL-2R on their surfaces. A
MAb specific for bovine IL-2R (anti-CD25) (44) which cross-
reacts with ovine CD25 became available after these exper-
iments were performed, and so stored cells were used to
assess the IL-2R status at the peak of the CD8+ lymphoblast
response (day 7 p.i. for sheep 649R; day 11 p.i. for sheep
683R). A proportion of the CD4+ lymphoblast and small
lymphocyte populations were positive for IL-2R, while the
CD8+ lymphoblasts at the peak of the CD8+ lymphoblast
wave were negative (Table 2). There was some loss of CD8+
cells on freezing and resuscitation, but there was no evi-
dence of a selective loss of IL-2R+ CD8+ lymphoblasts on
storage of ConA-stimulated lymphoblasts from persistently
infected sheep.
The percent -yb T-cell receptor-positive lymphoblasts
(T19-positive cells) (36) did not vary after MVV challenge of
the node, nor were there significant changes seen in the
percent CD4+ and -yb T-cell receptor-positive small lympho-
cytes (data not shown).
After MVV infection, the increase in percentage of surface
Ig (sIg)-positive lymphoblasts between day 0 and the maxi-
mum (Table 1) was much less striking than the increase in
CD8+ lymphoblasts exiting the node, but the peak number of
B lymphoblasts exiting virus-stimulated nodes (median, 4.1
TABLE 2. IL-2R expression of CD4+ and CD8+ lymphocytes at
the peak CD8+ lymphoblast output
CD4+ % IL-2R+ CD8+ % IL-2R+
Sheep no. or Day
sample p.i. Small Lympho- Small Lympho-
lymphocytes blasts lymphocytes blasts
649RW 7 8.5 18.0 0.7 1.3
32 14.2 14.0 2.8 1.4
683Rd -1 17.8 13.6 3.4 1.1
11 10.7 7.2 2.3 1.7
ConA stimulatedb
Fresh 27.3 48.7 1.7 32.9
Stored 36.8 58.8 7.8 43.7
a Efferent lymph cells were resuscitated from liquid nitrogen and washed,
and the CD4, CD8, and IL-2R expression of cells was determined by FACS
analysis. Preinfection samples for sheep 649R were not available, and so a
very late sample was used.
b Three-day ConA-stimulated (suboptimal concentration, 1.25 Fg/ml) effer-
ent lymph cells from a persistently infected sheep were analyzed immediately
(fresh) or stored under liquid nitrogen and then resuscitated and analyzed as
above.
x 106) was significantly higher than for mock-infected sheep
(0.8 x 106; P = 0.037). The number of sIg+ small lympho-
cytes was also increased but not significantly compared with
mock-infected controls (data not shown). The time course of
the B-cell changes showed considerable variability between
sheep. When the isotype of the sIg on B lymphocytes was
examined by two-color FACS to identify sIgM and sIgL or
sIgG coexpression, an slg isotype change from sIgM to sIgG
with time was seen both with MVV- and with mock-infected
sheep efferent B lymphoblasts (data not shown).
Time course of virus output. Evidence for viral replication
within the locally infected node and the relationship of this
viral replication to the developing immune response was
sought by quantitating the levels of infectious MVV or MVV
protein in both the lymph cells and plasma.
From day 6 p.i., MVV p25 antigen was detected in lymph
plasma in three of three sheep, with two distinct peaks
around days 6 to 10 and from day 22 onwards (Fig. 2A),
indicating that MVV replication was occurring. Despite the
presence of MVV p25 antigen, no infectious virus was
detected in lymph plasma by cocultivation on skin fibro-
blasts, but because of the nature of the assay, the p25 may be
part of a noninfectious virion. Only cell-associated infectious
virus could be isolated from four of five MVV-infected sheep
(Table 3), and this appeared maximally between days 9 and
14 p.i. (Fig. 2A). No infectious virus was isolated from sheep
671R. This sheep received the lowest dose of infectious
virus, but serum MVV-specific antibodies were detected
shortly following the cessation of surgical cannulation, indi-
cating that a persistent infection with MVV had been estab-
lished.
Gene amplification by MVV-specific PCR on DNA iso-
lated from efferent lymph cells from three of three sheep
during the period of infectious virus isolation (days 10 to 12)
revealed MVV-specific DNA (expected product size of 301
bases) (Fig. 2B and C, lanes 3 to 5). For sheep 649R, MVV
proviral DNA was detected in efferent lymph cells before
infectious virus was isolated (cGmpare Fig. 2B and C, lanes
4 and 6 to 11, with Fig. 2A). Thus, although proviral DNA
detection did not correlate absolutely with infectious virus
isolation, MVV-infected cells are present in efferent lymph.
The DNA PCR assay is not quantitative, but the requirement
for either nested PCR or high numbers of amplification
cycles (50 were used) to detect MVV DNA sequences
VOL. 67, 1993
5192 BIRD ET AL.
1500
a.
E
Oi-
' ID
a.
* -
Day post Infection
B
1 2 3 4 5 6 7 8 9 10 11 12 m
C
FIG. 2. Virus output in efferent lymph following MVV infection in three sheep. (A) Kinetics of cell-associated infectious virus and soluble
MVV p25. Infectious virus was detected by cocultivation of stored efferent lymph plasma or cells from infected sheep on sheep fibroblast
monolayers for 12 to 14 days and then subjected to immunofluorescent staining for MVVgag p15 in the fixed skin cells. MVVgag p25 antigen
in lymph plasma was quantitated by capture ELISA on rabbit anti-p25-coated ELISA plates. (B and C) MVV-specific DNA in efferent lymph
cells. DNA (500 ng) extracted from efferent lymph cells was amplified by using amplimers specific for the MVV LTR, and the products were
run on agarose gels. The molecular weight markers (m) were a HindIII-EcoRI double digest of A phage DNA. The arrow represents the
position of the 831-bp fragment. The expected MVV DNA product size is 301 bases. (B) Ethidium bromide-stained gel; (C) Southern blot of
a similar gel probed for MVV DNA sequences. Sources of samples: lanes 1 and 2, uninfected sheep 1060P, days -1 and 10, respectively; lane
3, infected sheep 683R, day 10; lane 4, sheep 649R, day 11; lane 5, sheep 657R, day 12; lanes 6 to 11, sheep 649R, days -1, 0, 6, 9, 12, and
14, respectively; lane 12, positive control DNA from MVV-infected fibroblasts in tissue culture.
suggests that MVV proviral DNA sequences were rare. The
frequency of MVW-infected cells in efferent lymph was
extremely low even at their peak, the median for four sheep
being equal to 11/106 cells (Table 3). Despite this low
frequency, the total number of infected cells disseminating
virus via the efferent lymphatic was sizeable when consid-
ered over time, with a median for four sheep of 3.1 x 104
TABLE 3. Frequency and total number of infectious virus-
associated cells exiting in efferent lymph following
acute MVV infection
Lymph node Challenge Day of Maximum Total infected
eep efferent duct dose (105 maxmmum frequency of cells (104
no. cannulated TCID50) virus virus-infected cls2 asoutput cells/106 cells cells/20 days)
657R Prefemoral 3.2 12 15.3 11.52
649R Prefemoral 15.0 14 7.35 1.61
683R Prefemoral 15.0 10 6.1 2.46
671R Popliteal 1.5 <0.5 0.
672R Popliteal 16.0 9 55.1 3.73
MVV-infected cells leaving the node during the first 20 days
p.i. (Table 3).
Interestingly, the main cell-associated infectious MVV
peak occurred just after or coincidentally with the major
lymphoblast response in efferent lymph (Table 1), but the
low frequency of infected cells has prevented identification
of the infected cell type. The peak of these cells was also
delayed relative to the first soluble MVV p25 antigen peak in
plasma by about 4 days. The second rise in p25 in lymph
plasma was not associated with a second wave of infected
cells, at least within the time course of the cannulations,
indicating that the p25 in lymph plasma may result from virus
replication within the node.
MVW-specific immune responses. (i) Antibody. MVV neu-
tralizing activity was not detected in the efferent lymph
plasma of three of three MVV-infected sheep before day 10
but thereafter rose steadily in titer with time (Fig. 3A). No
neutralizing activity was found in mock-infected sheep
lymph plasma. Preincubation of the lymph plasma with
polyclonal antibody to sheep Ig inhibited neutralization,
indicating that the neutralizing activity was antibody medi-
ated. By Western blotting (immunoblotting), an MVV gag
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FIG. 3. The time course of the MVV-specific antibody. (A)
Neutralizing activity of heat-inactivated lymph plasma was quanti-
tated from the reduction in infectivity of 500 TCID^o of MVV EVl
after overnight incubation at 4°C with dilutions of lymph plasma.
The titer represents the highest dilution giving 50% inhibition of
infectivity. (B) MVV p25-specific antibody. p25-specific antibody in
efferent lymph was quantitated by ELISA, using recombinant
p25-coated plates. The titer represents the highest dilution with an
optical density greater than twice background (no plasma). (C)
Soluble MVV p25 immune complexes in the efferent lymph of an
infected sheep. These complexes were detected in efferent lymph
plasma (sheep 649R) by capture ELISA on anti-p25-coated ELISA
plates developed with rabbit anti-sheep Ig antibody.
p25-specific antibody response can be detected in efferent
lymph as early as day 4 p.i., and an anti-env gpl35 response
can be detected by day 12, with an isotype change from IgM
to IgGl with time (data not shown). The appearance of
neutralizing activity coincided with the detection of IgGl
anti-MVV env gpl35 antibody (data not shown).
The anti-MVV p25 antibody response of infected sheep
quantitated by ELISA (Fig. 3B) detected specific antibody
from day 4 and in two of three sheep showed two peaks of
anti-p25 antibody around days 4 to 8 and 12 to 20. It is likely
that these two peaks coffespond to the IgM and IgGl isotype
responses, respectively. MW p25 antigen (Fig. 2A) was
detected at the same time as anti-p25 antibody in efferent
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FIG. 4. Proliferation of efferent lymph cells in response to re-
combinant human IL-2, ConA, and MVV antigen. Efferent lymph
cells were set up in culture with 20 U of recombinant human IL-2 per
ml (A) or 5 ig of ConA per ml (B) for 3 days or 4 pg of
sucrose-purified MVW antigen per ml and autologous PBMC (3:1
PBMC/efferent lymph cells) for 5 days (C). Cellular proliferation
was determined by [ H]thymidine incorporation. For 3-day cultures,
proliferation is expressed as specific proliferation = (mean cpm of
stimulated cultures) - (mean cpm of unstimulated cultures). Un-
stimulated counts ranged from 82 to 713 cpm. For 5-day cultures,
proliferation is expressed as stimulation index = (mean cpm of
antigen-stimulated cultures)/(mean cpm of unstimulated cultures),
with values for unstimulated cultures always being less than 3,400
cpm. Sheep were infected with MVW in the area draining to the
lymph node on day 0. Symbols: 0, sheep 649R; A, sheep 683R.
lymph plasma. During this period, soluble p25 immune
complexes were present in efferent lymph plasma (Fig. 3C).
(ii) T lymphocytes (proliferation to IL-2 and mitogen). The
functional activation state of efferent lymph cells was as-
sessed by measuring the proliferative capacity of the lym-
phocytes to respond to two nonspecific stimuli: a cytokine,
IL-2, and a mitogen, ConA.
When the response of efferent cells to human recombinant
IL-2 was studied, there were major peaks of proliferation in
response to IL-2 between days 4 and 8 p.i. (Fig. 4A) and in
one sheep a second wave of IL-2 responsiveness between
days 19 and 24 p.i. However, these peaks do not correspond
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TABLE 4. Cytotoxic activity of efferent lymph cells
Sheep % Specific 51Cr releasea at given days p.i.
no. Target cells 1-2 3-4 5 67 10-11 11-12 13-14 15-16 19-20
657RC
MVV infected
Autologous 1.1 t 2.8 7.4 ± 4.4 20.7 ± 2.3 33.8 t 2.6 1.5 ± 2.3
Heterologous -1.7 t 0.5 4.4 ± 2.6 1.8 ± 0.9 5.0 ± 0.3 0.7 ± 0.5
Mock infected
Autologous 3.2 ± 0.6 -0.9 t 0.8 -0.5 ± 1.6 1.1 ± 1.6 0.8 ± 0.9
Heterologous -2.2 ± 0.4 3.1 ± 0.1 -1.3 ± 0.4 -1.5 ± 1.8 1.6 ± 1.0
649Rd
MVV infected
Autologous 4.2 ± 3.9 14.3 ± 4.8 0.9 ± 3.4 -1.8 t 0.8 1.2 ± 0.5
Heterologous 5.7 ± 3.5 6.2 ± 5.7 14.1 ± 4.2 4.0 ± 1.0 12.2 ± 0.5
Mock infected
Autologous 0.5 ± 3.0 9.1 ± 1.9 1.5 ± 1.2 -0.4 t 0.6 0.2 ± 0.6
Heterologous 1.4 ± 1.4 0.3 ± 1.1 0.2 ± 2.0 8.2 ± 1.7 -8.1 ± 3.2
a Results shown at effector/target ratio of 50:1.
b Effector/target ratio of 15:1.
Assays also performed with cells from days -1 to 0 p.i.; no specific killing of MVV-infected autologous targets (data not shown).
d Assays also performed with cells from days -2 to -1, 7 to 8, 9 to 10, and 19 to 20 p.i.; no specific killing of MVV-infected autologous targets (data not shown).
to the peak output of CD8+ or CD4+ lymphoblasts in both
sheep. They also do not correspond consistently to any
peaks in cell, lymphoblast, or particular small lymphocyte
phenotype output (data not shown). The response of efferent
lymph cells to mitogenic stimulation was also analyzed (Fig.
4B). Just as with IL-2, there were two waves of proliferation
to ConA, with the minimal stimulation being seen between
days 10 and 16 p.i. Interestingly, the time p.i. when the
efferent lymphocytes were unresponsive to these external
stimuli corresponded to the period when maximal numbers
of virus-infected cells left the node (Fig. 2).
(iii) T lymphocytes (proliferation to MIW antigen). MVV-
specific lymphocyte proliferation could be seen in efferent
lymphocytes after day 15 p.i. (Fig. 4C; positive proliferation
was taken as stimulation index greater than 2). This prolif-
eration was also seen in response to recombinant gag p25
antigen but not ovalbumin or medium alone, and it required
the addition to cultures of autologous PBMC (collected
preinfection) to act as antigen-presenting cells (data not
shown) as there are few professional antigen-presenting cells
in efferent lymph (4, 29).
(iv) T lymphocytes (direct lysis of MVW-infected autologous
skin cells). Fresh efferent lymphocytes were used in cytotox-
icity assays against "Cr-labeled autologous MVV-infected
skin cells. In one sheep (657R) of five tested, specific lysis of
MVV-infected autologous skin cells could be seen, and this
was between days 10 and 14 p.i. (Table 4). The cytotoxic
activity was apparently MHC restricted, as there was no
lysis of MVV-infected heterologous cells. This cytotoxicity
was during the CD8+ lymphoblast peak of 657R. However,
none of the other four MVV-challenged (or mock-infected)
sheep ever showed MVV-specific cytotoxicity of autologous
cells even at effector/target ratios of 100:1 during the CD8+
lymphoblast response (Table 4, sheep 649R). All cells in
virus-infected target cultures expressed gag antigen by im-
munofluorescent staining using an anti-gag MAb, and com-
plement lysis of cells could be shown with anti-MVV sheep
serum and rabbit complement (data not shown).
DISCUSSION
Lentiviral infections are characterized by a long asymp-
tomatic period, when virus is rarely detected and viral gene
expression is highly restricted in the host, and a slow
progression of disease in the face of specific B- and T-cell
immune responses. There is now evidence that during this
time the lymph node is a major reservoir for the virus (10,
50). It is therefore likely that the acute events associated
with initial virus infection of a lymph node may be of
considerable importance in determining viral persistence and
the subsequent course of disease. Therefore, the study
within lymphoid tissue of the early T- and B-cell immune
response to local lentiviral infection and the correlation of
this response to viral replication are potentially of great
value in furthering our understanding of the pathogenesis of
lentiviral disease. We have shown here that after infection
with MVV, sheep mount an antiviral immune response (both
T cell and antibody), but despite this, viral replication and
dissemination occur.
However, closer study reveals differences in the immune
response to MVV (and other lentiviruses) and the immune
response induced by other viruses. These include the acti-
vation state of the CD8+ lymphoblasts and the ability of the
lymph cells to respond to external stimuli during the course
of infection.
In most species, activated T lymphocytes have been
shown to be lymphoblastoid, to synthesize DNA, and to
express MHC class II antigens and IL-2R (11, 12, 18, 21, 32,
60). The CD8+ lymphoblasts, at the peak of the response to
MVV, were a homogeneous population expressing MHC
class II DR and DQ (DQ at a lower intensity than DR).
However, they did not express IL-2R (CD25), while a
proportion of the CD4+ lymphoblasts were positive for
IL-2R expression. Early after intravenous infection of
rhesus monkeys with the simian immunodeficiency virus
SIVMac, an increase in the number and percentage of CD8+
cells in the peripheral lymph nodes was reported (52). These
cells express MHC class II DR but not IL-2R. Similarly,
HIV-infected patients exhibit circulating CD8+ DR' cells
negative for IL-2R (51, 59). These cells are defective in their
response to anti-CD3 and anti-CD2 or mitogen stimulation,
even in the presence of additional IL-2 or IL-4. It is therefore
apparent that a common feature of the immune response to
lentiviruses (not only immunodeficiency viruses) is the in-
duction of CD8+ lymphocytes in a defective maturation state
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(59). This is not seen in the immune response to lymphocytic
choriomeningitis virus (LCMV) in mice. In that case, CD8+
lymphocytes are a high percentage of the regional lymph
node cells on day 6 p.i., but these cells express IL-2R and
will proliferate in response to recombinant IL-2 (35).
In lentiviral infections, the absolute peripheral blood
CD8+ lymphocyte numbers do not reflect any measurable
virus-specific immune function (48), and it has been postu-
lated that they are immune regulators. We have no evidence
from our results for this. The CD8+ lymphoblasts detected in
our study do not appear to act as suppressor cells, as the
time of their appearance in the efferent lymph does not
always correspond to the time at which efferent lymph cells
do not respond to cytokine or mitogen stimulation. Nor do
the cells have any consistent cytotoxic activity, since in only
one of the five sheep was any cell-mediated cytotoxicity
demonstrable at this early stage of infection.
The primary B-cell response to MVV was characterized
by a significantly increased output of Ig+ lymphoblasts in
efferent lymph and the appearance of MVV-specific anti-
body in lymph plasma by day 4. This is the characteristic
time for the humoral response to primary virus challenge.
However, MVV neutralizing antibody was not detected until
days 12 to 14 p.i., which was when virus was seen dissem-
inating from the lymph node. All detectable virus was cell
associated, and neutralizing antibody (assayed on cell-free
virus) might not be expected to neutralize virally infected
cells. Levels ofgag p25 antigen in lymph plasma temporarily
decreased as initial antibody titers rose. p25 antigen may, in
part, represent cell-free virus which has been neutralized by
antibody. As we never detected cell-free virus, neutralizing
antibody titers may be sufficient to control spread of virus by
this route. In SIV and HIV, the presence of neutralizing
antibody also correlates with a drop in p24 antigenemia and
is associated with a longer survival time (6, 66). However,
the rising levels of p25 antigen from day 20 onwards in this
study suggest that MVV replication and the number of
infected cells within the lymph node are increasing and are
not controlled by antibody.
In contrast, viral dissemination from the node was limited
in that detectable infectious MVV left the node as a wave of
virally infected cells (maximum number of infected cells
between days 10 and 14 p.i.), suggesting that immune
surveillance is effective apart from this period. What
changes therefore occur within the immune system between
days 10 to 14 p.i. that allow dissemination of this form of
virus? One explanation is that T lymphocytes are unable to
respond to virally infected cells at this time. It is during this
period that efferent lymph cells do not proliferate to IL-2 and
the mitogen ConA, suggesting that T lymphocytes unrespon-
sive to many different stimuli are induced by the virus,
allowing its dissemination. Mechanisms which could cause
this lack of response include anergy and suppressor lympho-
cyte activity (38). No assays have been carried out to test
whether the decrease in proliferative ability seen here was
due to anergy or suppression. However, unresponsive lym-
phocytes have been recorded in the acute response to
cytomegalovirus (5) and Epstein-Barr virus (53), and the
latter group has shown that this effect is due to the presence
of suppressor cells. It is also well documented in HIV that
there are defects in T-cell function early after infection but
before the manifestation of clinical disease (22). It is inter-
esting that these viruses all cause persistent infections
through latent or restricted replication states in hemopoietic
cells. It may well be that the induction of nonfunctional T
lymphocytes allows the dissemination of virally infected
cells within the host through the normal lymph/blood trans-
port system.
We have evidence for MVV-specific T-cell responses.
Antibody was detected in the lymph plasma from day 4 p.i.
onwards, and as this response requires T-cell help, it is likely
that MVV-specific T cells are present in the node from this
time. However, MVV-specific proliferative responses were
not detected in efferent lymph cells until day 15 p.i. In
persistently infected sheep, the proliferating cell in this assay
was principally CD4+ (54a). The specific T-cell response
increased as cell-associated virus exiting the lymph node
decreased. Therefore, the increase in MVV-specific CD4+
lymphocytes may be responsible for the reduction of cell-
associated virus. A model murine retroviral infection has
been shown to require both CD4+ and CD8+ lymphocytes
for protection (28).
Direct MVV-specific cytotoxic activity was detected in
efferent lymph cells but in only one of five sheep between
days 10 and 14 p.i. A similar proportion of HIV patients
show cytotoxic T-lymphocyte (CTL) activity in unstimu-
lated peripheral blood lymphocytes (20). However, in HIV
infection, there are reports that CD8+ CD57+ lymphocytes
produce a soluble factor inhibiting CTL lysis of target cells
(1, 58). A similar mechanism operating in sheep could
account for the small number of sheep exhibiting direct
cytotoxicity in our study. After primary infection with
vaccinia virus (30, 31), cytotoxic lymphocytes were detected
in efferent lymph at days 4 to 7 p.i. This CTL activity was
associated with the lymphoblast population of efferent
lymph cells, and in sheep 657R, the cytotoxic activity also
corresponded to the lymphoblast wave. In LCMV infection
in mice, LCMV-specific CTL appear on day 6 p.i. in the
regional lymph node (35), and SIVmac infection of rhesus
monkeys also induced CTL in the peripheral lymph nodes in
four of eight monkeys; however, the authors do not say at
which time these responses were induced (52). The induction
of precursor CTL was not assayed in the work presented
here.
Interestingly, the CTL activity in sheep 657R was detected
during the period when cell-associated virus exited the
lymph node, and so this activity had not protected this sheep
from viral dissemination. Cell-associated virus was detected
by cocultivation of efferent lymph cells on indicator cells.
Before cocultivation, MVV may be in a restricted replication
state within the host cell and so may not express viral
antigen to the immune system. In HIV and SIV, CTL and
precursor CTL are present in animals at the same time as
virus may be isolated and during disease progression. How-
ever, there may be a role for CD8+ cells in reducing viral
load, as it has been shown that CTL activity decreases in
HIV-infected patients with advanced disease in which virus
production is increased (48).
There is evidence that the immune response may activate
as well as limit lentiviral infection. The LTR of T-cell-tropic
lentiviruses HIV and SIV contain NF-Kb-binding elements
responsive to cytokine activation of T cells (reviewed in
reference 56), and the virulence of one SIV clone is associ-
ated with the ability of this clone to directly activate lym-
phocytes (13). Similarly, the LTR in MVV is known to
contain a number of AP1 elements (14) which may be
responsive to monokines generated during an immune re-
sponse. Postinfection inoculation with purified MVV in
Freund's adjuvant enhanced the severity of the lesions in
MVV infection (47), as did prior vaccination with inactivated
caprine arthritis-encephalitis virus (41). Immune activation
in vivo generated by purified protein derivative (PPD) also
VOL. 67, 1993
5196 BIRD ET AL.
stimulated MVV replication and dissemination in efferent
lymph (our unpublished results). During acute infection of
the node by MVV, the developing immune response to the
virus may promote viral replication. The timing of both
MVV replication (as measured by p25 levels) and late
MVV-infected cell dissemination would support this.
By whatever mechanism, MVV-infected cells evaded the
host immune response and disseminated from the lymph
node. The frequency of these cells was very low, less than 1
in 104, but over time, this added up to a considerable number
of infectious centers (more than 104). A restricted viral
replication state is well characterized in persistent MVV in
vivo infection (3), and in a lung model of early MVV
infection, Geballe et al. (15) believe that a restricted state
may be established by day 4 p.i. In this study, we do not
know the replication state of the infected cell, as in situ
hybridization revealed rare MVV RNA-positive efferent
lymph cells (1 to 5 per 106 cells) (57), but no MVVgag p15-
or p25-positive cells were detected by immunofluorescence
during the period when infectious MVV was detected (un-
published results). The lineage of these rare infected cells is
unknown. Efferent lymph contains predominantly lympho-
cytes, but rare macrophage-like cells (by morphology and
nonspecific esterase positivity) can be detected at a fre-
quency similar to that of cell-associated virus.
Although here we have studied the acute immune events
involved in MVV infection, already some of the pathogenic
mechanisms are evident. The continuing virus replication in
the presence of MVV-specific antibody leads to immune
complex formation, and these complexes may contribute to
lesion formation in a variety of organs. Similarly, the infil-
tration of many MVV-affected tissues by CD8+ lymphocytes
may follow the initial activation of this cell population
reported here.
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